1. 056 Efficacy and safety of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis over 48 weeks: a randomized, placebo-controlled, phase 2 study. (29th July 2019) Authors: Montalban, Xavier; Arnold, Douglas L; Weber, Martin S; Staikov, Ivan; Piasecka-Stryczynska, Karolina; Gillett, Alan; Martin, Emily C; Syed, Sana; Dangond, Fernando; Wolinsky, Jerry S Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 90(2019)e7 Page Start: A18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗